Beta
Today
Capital & Financial MarketsPortfolio & StrategyRegulatory & Legal 28 Oct 2026

UPM opens remedy talks after EU restates concerns over Sappi graphic paper JV

UPM said the European Commission restated its serious concerns about the planned graphic paper joint venture with Sappi in early October 2026. UPM has opened discussions on potential remedies while maintaining that its arguments address the concerns, and the transaction remains subject to merger control approval. UPM's third-quarter 2026 sales were EUR 2,202m and comparable EBIT fell 8% to EUR 131m amid customer destocking.

Why this mattersRemedy talks signal that the UPM-Sappi graphic paper consolidation may clear only with concessions, which could change the capacity the joint venture brings together.

  • The European Commission restated serious concerns about the UPM-Sappi graphic paper joint venture in early October 2026
  • UPM has opened discussions on potential remedies while saying it believes in the strength of its arguments
  • The joint venture remains subject to merger control approvals
  • UPM Q3 2026 sales were EUR 2,202m against EUR 2,226m; comparable EBIT fell 8% to EUR 131m
  • Q3 operating cash flow rose to EUR 420m from EUR 218m
  • The plywood business is to start trading as WISA Group on Nasdaq Helsinki in November
UPM Sappi counterparty European Commission counterparty
Sources news.cision.com
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-10-31 · Edited before publication: Remedy talks are reported by UPM ('we'), not as a joint step by both companies. 'No revised timeline disclosed' is not in the source. UPM's position that its arguments address the concerns added for balance.
  • 2026-10-31 · Edited before publication: The 'why it matters' line was weak and partly speculative: a deal cleared with remedies would not leave the partners without a route. Rewritten.